 |
9 Diseases |  |
2 Trials |
|
2 Trials |  |
30 News |  |
- | afimoxifene / Besins Healthcare
Trial completion: Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast (clinicaltrials.gov) - Feb 22, 2024
P2, N=194, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed
- | afimoxifene / Besins Healthcare
Trial completion date, Trial primary completion date: Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast (clinicaltrials.gov) - Apr 26, 2023
P2, N=194, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Trial completion date: Apr 2023 --> Oct 2023 | Trial primary completion date: Apr 2023 --> Oct 2023
- | afimoxifene / Besins Healthcare
Enrollment open, Enrollment change: Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast (clinicaltrials.gov) - Jan 30, 2023
P2, N=156, Recruiting, Sponsor: Northwestern University
Trial completion date: Apr 2023 --> Oct 2023 | Trial primary completion date: Apr 2023 --> Oct 2023 Suspended --> Recruiting | N=120 --> 156
- | afimoxifene / Besins Healthcare
Trial primary completion date: Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast (clinicaltrials.gov) - Jan 5, 2023
P2, N=120, Suspended, Sponsor: Northwestern University
Suspended --> Recruiting | N=120 --> 156 Trial primary completion date: Jun 2023 --> Jan 2024
- | afimoxifene / Besins Healthcare
Trial primary completion date: Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast (clinicaltrials.gov) - Dec 30, 2022
P2, N=194, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jun 2023 --> Jan 2024 Trial primary completion date: Oct 2021 --> Apr 2023
- | afimoxifene / Besins Healthcare
Trial completion date, Trial suspension, Trial primary completion date: Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast (clinicaltrials.gov) - Nov 4, 2022
P2, N=120, Suspended, Sponsor: Northwestern University
Trial primary completion date: Oct 2021 --> Apr 2023 Trial completion date: Jun 2023 --> Jun 2024 | Recruiting --> Suspended | Trial primary completion date: Jun 2022 --> Jun 2023
- | afimoxifene / Besins Healthcare
Trial primary completion date: Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast (clinicaltrials.gov) - Aug 16, 2022
P2, N=152, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Jun 2023 --> Jun 2024 | Recruiting --> Suspended | Trial primary completion date: Jun 2022 --> Jun 2023 Trial primary completion date: Apr 2023 --> Oct 2021
- | afimoxifene / Besins Healthcare
Trial completion date, Trial primary completion date: Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast (clinicaltrials.gov) - Aug 12, 2022
P2, N=152, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Apr 2023 --> Oct 2021 Trial completion date: Oct 2021 --> Apr 2023 | Trial primary completion date: Oct 2021 --> Apr 2023
- | afimoxifene / Besins Healthcare
Journal: Evaluation of human adipose-derived stromal cell behaviour following exposure to Tamoxifen. (Pubmed Central) - Aug 12, 2022
Trial completion date: Oct 2021 --> Apr 2023 | Trial primary completion date: Oct 2021 --> Apr 2023 At physiologically relevant doses, Tamoxifen treatment did not result in any deleterious effect on ASC survival and functionality and is unlikely to negatively impact ASC based breast reconstruction strategies for breast cancer patients receiving this adjuvant hormonal therapy.
- | afimoxifene / Besins Healthcare
Enrollment closed, Trial completion date: Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast (clinicaltrials.gov) - Sep 13, 2021
P2, N=152, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
At physiologically relevant doses, Tamoxifen treatment did not result in any deleterious effect on ASC survival and functionality and is unlikely to negatively impact ASC based breast reconstruction strategies for breast cancer patients receiving this adjuvant hormonal therapy. Recruiting --> Active, not recruiting | Trial completion date: Sep 2022 --> Oct 2021
- | tamoxifen / Generic mfg.
Journal: Synthesis of Tamoxifen-Artemisinin and Estrogen-Artemisinin Hybrids Highly Potent Against Breast and Prostate Cancer. (Pubmed Central) - Jun 16, 2021
The most potent compounds were the estrogen-artemisinin hybrids 27 and 28 (EC 50 (PC-3) = 1.18 µM and 1.07 µM, correspondingly) against prostate cancer and hybrid 23 (EC 50 (MCF-7) = 2.08 µM) against breast cancer. These findings demonstrate the high potential of hybridization of artemisinin and estrogens to further improve their anticancer activities and to produce synergistic effects between linked pharmacophores.
- | afimoxifene / Besins Healthcare
Trial completion date, Trial primary completion date: Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast (clinicaltrials.gov) - Mar 4, 2021
P2, N=152, Recruiting, Sponsor: M.D. Anderson Cancer Center
These findings demonstrate the high potential of hybridization of artemisinin and estrogens to further improve their anticancer activities and to produce synergistic effects between linked pharmacophores. Trial completion date: Sep 2020 --> Sep 2022 | Trial primary completion date: Sep 2020 --> Sep 2021
- | afimoxifene / Besins Healthcare
Enrollment open: Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast (clinicaltrials.gov) - Dec 4, 2020
P2, N=120, Recruiting, Sponsor: Northwestern University
Trial completion date: Sep 2020 --> Sep 2022 | Trial primary completion date: Sep 2020 --> Sep 2021 Not yet recruiting --> Recruiting
- | tamoxifen / Generic mfg.
Journal: Elucidating Binding Sites and Affinities of ERα Agonists and Antagonists to Human Alpha-Fetoprotein by In Silico Modeling and Point Mutagenesis. (Pubmed Central) - Nov 12, 2020
We performed in silico point substitutions of amino acid residues to confirm their roles in HAFP-ligand interactions and showed that Thr132, Leu138, His170, Phe172, Ser217, Gln221, His266, His316, Lys453, and Asp478 residues, along with two disulfide bonds (Cys224-Cys270 and Cys269-Cys277), have key roles in both HAFP-estrogen and HAFP-antiestrogen binding. Data obtained in our study contribute to understanding mechanisms underlying protein-ligand interactions and anticancer therapy strategies based on ERα-binding ligands.
- || afimoxifene / Besins Healthcare, Soltamox (tamoxifen citrate) / Jazz
Trial completion date, Trial primary completion date: Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast (clinicaltrials.gov) - Mar 2, 2020
P2b, N=100, Recruiting, Sponsor: Northwestern University
Data obtained in our study contribute to understanding mechanisms underlying protein-ligand interactions and anticancer therapy strategies based on ERα-binding ligands. Trial completion date: Jul 2019 --> Jul 2023 | Trial primary completion date: Jul 2019 --> Jul 2022
- | afimoxifene / Besins Healthcare
Trial initiation date: Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast (clinicaltrials.gov) - Dec 17, 2019
P2, N=120, Not yet recruiting, Sponsor: Northwestern University
Trial completion date: Jul 2019 --> Jul 2023 | Trial primary completion date: Jul 2019 --> Jul 2022 Initiation date: Jul 2019 --> Jan 2020
- | afimoxifene / Besins Healthcare
Trial primary completion date: Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast (clinicaltrials.gov) - Nov 14, 2019
P2, N=152, Recruiting, Sponsor: M.D. Anderson Cancer Center
Initiation date: Jul 2019 --> Jan 2020 Trial primary completion date: Sep 2019 --> Sep 2020
- afimoxifene / BHR Pharma
Low dose tamoxifen and other approaches to improve chemoprevention uptake (Stars at Night Ballroom 1&2 -3rd level) - Aug 19, 2019 - Abstract #SABCS2019SABCS_24;
Initial findings indicate the feasibility of this approach in attaining active concentrations in the breast and modulation of Ki-67 (Lee et al Cancer Chemother Pharmacol. 2015).
- | afimoxifene / Besins Healthcare
New P2 trial: Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast (clinicaltrials.gov) - Jul 4, 2019
P2, N=120, Not yet recruiting, Sponsor: Northwestern University
- | afimoxifene / Besins Healthcare
Trial completion date, Trial primary completion date: Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast (clinicaltrials.gov) - May 9, 2019
P2, N=152, Recruiting, Sponsor: M.D. Anderson Cancer Center
2015). Trial completion date: May 2019 --> Sep 2020 | Trial primary completion date: May 2019 --> Sep 2019
- | afimoxifene / Besins Healthcare
Enrollment open: Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast (clinicaltrials.gov) - Nov 24, 2017
P2, N=152, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: May 2019 --> Sep 2020 | Trial primary completion date: May 2019 --> Sep 2019 Not yet recruiting --> Recruiting
- |||| afimoxifene / Besins Healthcare, Soltamox (tamoxifen citrate) / Jazz
Enrollment open: Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast (clinicaltrials.gov) - Aug 21, 2017
P2b, N=100, Recruiting, Sponsor: Northwestern University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | afimoxifene / Besins Healthcare, Soltamox (tamoxifen citrate) / Jazz
Trial initiation date: Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast (clinicaltrials.gov) - Apr 16, 2017
P2b, N=100, Not yet recruiting, Sponsor: Northwestern University
Not yet recruiting --> Recruiting Initiation date: Mar 2017 --> Jun 2017
- | afimoxifene / Besins Healthcare
New P2 trial: Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast (clinicaltrials.gov) - Feb 24, 2017
P2, N=152, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | afimoxifene / Besins Healthcare, Soltamox (tamoxifen citrate) / Jazz
New P2b trial: Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast (clinicaltrials.gov) - Dec 15, 2016
P2b, N=100, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | tamoxifen / Generic mfg.
Trial completion, Enrollment change, Trial initiation date: 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ (clinicaltrials.gov) - Jul 21, 2015
P2b, N=27, Completed, Sponsor: Northwestern University
Initiation date: Mar 2017 --> Jun 2017 Active, not recruiting --> Completed | N=112 --> 27 | Initiation date: Mar 2010 --> Dec 2009
- tamoxifen / Generic mfg.
Enrollment closed: 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ (clinicaltrials.gov) - Apr 30, 2013
P2b, N=112, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=112 --> 27 | Initiation date: Mar 2010 --> Dec 2009 Suspended --> Active, not recruiting